Short Duration Therapy of Acute Hepatitis C Genotypes 1 or 4

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2017

Primary Completion Date

December 31, 2018

Study Completion Date

September 16, 2019

Conditions

Acute Hepatitis CHIV

Interventions

DRUG

Grazoprevir/Elbasvir

Once-daily, oral grazoprevir/elbasvir combination therapy at fixed-dose (100mg/50mg) for 8 weeks

Trial Locations (6)

CHU de Lyon, Lyon

Hôpital Saint-Antoine, Paris

Hôpital La Pitié-Salpêtrière, Paris

Hôpital Bichat, Paris

Hôpital Tenon, Paris

CHU de Nice, Nice

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

lead

Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba

OTHER

NCT02886624 - Short Duration Therapy of Acute Hepatitis C Genotypes 1 or 4 | Biotech Hunter | Biotech Hunter